Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer

San Diego, CA, September 29, 2026 — Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of the first peer-reviewed clinical data from the Phase 1 study of VVD-214, its investigational oral inhibitor of Werner helicase (WRN), in Nature Medicine. The […] The post Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer appeared first on Vividion Therapeutics .